SM-20302, a novel GPIIb/IIIa antagonist, has shown a selective antithrombotic activity without increasing the risk of hemorrhage in vivo - Sakurama, T; Horisawa, S; Kurata, H; Kishimoto, H; Nakano, M; Fukuoka, T; Kohda, A; Kaneko, M (Thromb Haemost, 1997)
Supplement: 7.